JP3384841B2 - Baking soda dialysis agent - Google Patents

Baking soda dialysis agent

Info

Publication number
JP3384841B2
JP3384841B2 JP17977293A JP17977293A JP3384841B2 JP 3384841 B2 JP3384841 B2 JP 3384841B2 JP 17977293 A JP17977293 A JP 17977293A JP 17977293 A JP17977293 A JP 17977293A JP 3384841 B2 JP3384841 B2 JP 3384841B2
Authority
JP
Japan
Prior art keywords
acid
dialysis agent
layer
organic acid
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP17977293A
Other languages
Japanese (ja)
Other versions
JPH06335527A (en
Inventor
澄廣 白石
武夫 菊地
繁幸 野村
康三 弓狩
Original Assignee
味の素ファルマ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 味の素ファルマ株式会社 filed Critical 味の素ファルマ株式会社
Priority to JP17977293A priority Critical patent/JP3384841B2/en
Publication of JPH06335527A publication Critical patent/JPH06335527A/en
Application granted granted Critical
Publication of JP3384841B2 publication Critical patent/JP3384841B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、炭酸水素イオンを含有
する透析液、すなわち重曹透析液を調製するための固形
製剤に関するものである。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a solid preparation for preparing a dialysate containing hydrogen carbonate ions, that is, a sodium bicarbonate dialysate.

【0002】[0002]

【従来の技術】近年、下記のような重曹透析液の需要が
増加している。 Na+ 120〜150 mEq/l K+ 0.5〜3.0 mEq/l Ca++ 1.5〜4.5 mEq/l Mg++ 0〜2.0 mEq/l Cl- 90〜135 mEq/l HCO3 - 20〜 35 mEq/l CH3 CO2 - 5〜 10 mEq/l ブドウ糖 0〜2.5 g/l しかし、このような組成の透析液は、1人1回の血液透
析に大量(約350リットル)使用され、しかも製剤的
に不安定なことから、使用直前に調製せざるを得ず、古
くは各種電解質の正確な秤量、溶解、pH調整など煩雑
な作業を要するものであった。
2. Description of the Related Art In recent years, the demand for the following sodium bicarbonate dialysate has been increasing. Na + 120~150 mEq / l K + 0.5~3.0 mEq / l Ca ++ 1.5~4.5 mEq / l Mg ++ 0~2.0 mEq / l Cl - 90~135 mEq / l HCO 3 - 20~ 35 mEq / l CH 3 CO 2 - 5~ 10 mEq / l glucose 0 to 2.5 g / l, however, dialysate having such a composition is the one single hemodialysis Since a large amount (about 350 liters) is used and the formulation is unstable, it has to be prepared just before use, and in the old days, it requires complicated work such as accurate weighing, dissolution, and pH adjustment of various electrolytes. there were.

【0003】そこで前記作業を軽減するものとして、1
人1回分の包装単位で、必要な成分中炭酸水素ナトリウ
ムを別にした濃厚原液(約11リットル)が市販される
ようになった。しかし、運搬、保管場所、透析液調製時
の取り扱い等において十分改良されたとは言えず、その
後も種々の提案がなされている。例えば、特開平3−7
4331号公報には、重曹透析液調製に必要な成分を、
カルシウム成分を含み炭酸水素ナトリウムを含まない群
と炭酸水素ナトリウムを含みカルシウム成分を含まない
群とに分け、前者にはpH調整剤としての酢酸を含ま
せ、両群をそれぞれ造粒して混合した透析用剤が開示さ
れている。この発明は、所定量の透析用剤を単に計算量
の水に溶解するだけで重曹透析液の調製ができるように
したものであるが、pH調整剤として液体の酸が使用さ
れているため、たとえ少量であっても経時的に酸と炭酸
水素ナトリウムの反応が進み、炭酸水素イオン含量の減
少をもたらす虞があり、さらには、長期保存中に造粒物
の凝集が生じ、取り扱いに不便を来す可能性があるなど
の問題点を有している。
To reduce the above work, therefore, 1
A concentrated stock solution (about 11 liters) from which sodium hydrogen carbonate as a necessary component has been removed has been put on the market in a packaging unit for one person. However, it cannot be said that it has been sufficiently improved in transportation, storage location, handling during preparation of dialysate, and various proposals have been made since then. For example, Japanese Patent Laid-Open No. 3-7
No. 4331 discloses components necessary for preparation of sodium bicarbonate dialysate,
It was divided into a group containing calcium component and no sodium hydrogen carbonate and a group containing sodium hydrogen carbonate and no calcium component. The former was mixed with acetic acid as a pH adjuster, and both groups were granulated and mixed. A dialysis agent is disclosed. This invention is a sodium bicarbonate dialysate can be prepared by simply dissolving a predetermined amount of dialysis agent in a calculated amount of water, but since a liquid acid is used as a pH adjusting agent, Even if the amount is small, the reaction between the acid and sodium hydrogencarbonate may proceed over time, resulting in a decrease in the hydrogencarbonate ion content.Furthermore, agglomeration of the granulated product may occur during long-term storage, which makes handling inconvenient. There is a problem that it may come.

【0004】[0004]

【発明が解決しようとする課題】本発明の課題は、重曹
透析液を調製するために必要な電解質とpH調整剤を含
む固形製剤であって、安定性に優れ、用時に水に速やか
に溶ける透析用剤を提供することにある。
An object of the present invention is a solid preparation containing an electrolyte and a pH adjusting agent necessary for preparing a sodium bicarbonate dialysate, which is excellent in stability and dissolves rapidly in water when used. To provide a dialysis agent.

【0005】[0005]

【課題を解決するための手段】本発明者らは、透析用剤
に必要な各電解質、さらには必要に応じて添加するブド
ウ糖の安定性及び吸湿性について考慮しながら、pH調
整剤をも含めた安定な固形製剤の可能性について鋭意研
究した。その結果、pH調整剤として薬理学的に許容さ
れる固体の有機酸を使用し、必要な成分を、有機酸を含
み重炭酸塩を含まない群(A群)、有機酸及び重炭酸塩
を共に含まない群(B群)及び重炭酸塩を含み有機酸を
含まない群(C群)に分け、各群をB群からなる層を中
間にして積層した製剤にすることにより、前記課題が解
決できることを見出した。本発明はその知見に基づいて
完成したものである。
DISCLOSURE OF THE INVENTION The inventors of the present invention include a pH adjusting agent while considering the stability of each electrolyte necessary for a dialysis agent and the stability and hygroscopicity of glucose added as necessary. We have conducted intensive studies on the possibility of stable and stable solid preparations. As a result, a solid organic acid which is pharmacologically acceptable is used as a pH adjuster, and the necessary components are a group containing an organic acid and no bicarbonate (group A), an organic acid and a bicarbonate. The above problems can be solved by dividing into a group not containing both (group B) and a group containing bicarbonate and not containing an organic acid (group C), and forming a formulation in which each group is laminated with a layer consisting of group B in the middle. I found that I could solve it. The present invention has been completed based on the findings.

【0006】すなわち、本発明は、少なくともNa+
Ca++、Cl- 及びHCO3 - を含有する透析液の調製
に必要な電解質と薬理学的に許容される固体の有機酸と
を含有する積層型製剤であって、前記有機酸を含み重炭
酸塩を含まない層と重炭酸塩を含み前記有機酸を含まな
い層が中間層を挟んで積層されてなる透析用剤を提供す
るものである。
That is, the present invention provides at least Na + ,
What is claimed is : 1. A multi-layered preparation comprising an electrolyte necessary for the preparation of a dialysate containing Ca ++ , Cl and HCO 3 and a pharmacologically acceptable solid organic acid, which contains the organic acid. The present invention provides a dialysis agent in which a layer containing no carbonate and a layer containing bicarbonate and not containing the organic acid are laminated with an intermediate layer interposed therebetween.

【0007】前記固体の有機酸としては、例えばクエン
酸、酒石酸、マレイン酸、オキサロ酢酸、イソクエン
酸、リンゴ酸等を挙げることができ、中でもクエン酸が
好ましい。これらの有機酸は1種のみならず2種以上を
使用してもい。
Examples of the solid organic acid include citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid, malic acid and the like, with citric acid being preferred. These organic acids may be used alone or in combination of two or more.

【0008】本発明に用いられる電解質は薬理学的に許
容されるものでなければならない。例えば、従来の技術
の項に記載した重曹透析液の成分を与えるものとして、
炭酸水素ナトリウム、炭酸水素カリウム、塩化ナトリウ
ム、塩化カリウム、塩化カルシウム、塩化マグネシウ
ム、酢酸ナトリウム、酢酸カリウム、グルコン酸カルシ
ウム等を挙げることができる。本発明を構成する顆粒剤
は、上記のような電解質と共に、血液中に含まれるその
他の成分、例えばブドウ糖等を含むことができる。
The electrolyte used in the present invention must be pharmacologically acceptable. For example, as giving the ingredients of the baking soda dialysate described in the section of the prior art,
Examples thereof include sodium hydrogen carbonate, potassium hydrogen carbonate, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, potassium acetate, calcium gluconate and the like. The granules constituting the present invention can contain other components contained in blood, such as glucose, in addition to the electrolyte as described above.

【0009】本発明の透析用剤に含まれる成分の好まし
い配合範囲を、透析液調製後の組成範囲で示せば下記の
如くであり、そのpHは7.0〜8.0、より好ましく
は7.2〜7.6である。 Na+ 120 〜150 mEq/l K+ 0 〜 4 mEq/l Ca++ 1 〜 6 mEq/l Mg++ 0 〜 2 mEq/l Cl- 90 〜135 mEq/l CH3 COO- 2 〜 15 mEq/l HCO3 - 10 〜 40 mEq/l 固体の有機酸 1 〜 5 mEq/l ブドウ糖 0 〜 10 g/l
The preferred blending range of the components contained in the dialysis agent of the present invention is shown below in terms of the composition range after preparation of the dialysate, and the pH thereof is 7.0 to 8.0, more preferably 7: .2 to 7.6. Na + 120 ~150 mEq / l K + 0 ~ 4 mEq / l Ca ++ 1 ~ 6 mEq / l Mg ++ 0 ~ 2 mEq / l Cl - 90 ~135 mEq / l CH 3 COO - 2 ~ 15 mEq / l HCO 3 - 10 ~ 40 mEq / l solid organic acid 1 ~ 5 mEq / l dextrose 0 ~ 10 g / l

【0010】本発明透析用剤の製造に当り、化合物を選
択し配合割合を設定する場合は、例えば上記に基づいて
各成分の濃度を設定し、各成分を供給できる化合物の組
合せにより逆算すればよい。
In the production of the dialysis agent of the present invention, when a compound is selected and a mixing ratio is set, for example, the concentration of each component is set based on the above, and back calculation is carried out by the combination of compounds capable of supplying each component. Good.

【0011】本発明透析用剤の剤形としては、芯物質
(核)、内層、中間層及び外層からなる積層型の球形顆
粒剤が好ましい。また、これらの各層を形成するに当
り、それぞれに好ましい化合物群を示せば次の如くであ
る。 芯物質(核) 塩化ナトリウム 内層 固体の有機酸(クエン酸、酒石酸、マ
レイン酸、オキサロ酢酸、イソクエン酸、リンゴ酸)、
酸性塩(塩化カルシウム、塩化マグネシウム) 塩化ナトリウム、塩化カリウム、ブドウ糖 中間層 塩化ナトリウム、塩化カリウム、酢酸
ナトリウム、酢酸カリウム、グルコン酸カルシウム、ブ
ドウ糖 外層 重炭酸塩(炭酸水素ナトリウム、炭酸
カリウム)、塩化ナトリウム、塩化カリウム、酢酸ナト
リウム、酢酸カリウム、グルコン酸カルシウム、ブドウ
糖 上記において外層に含ませる化合物が特に重要である。
すなわち、外層に重炭酸塩を単独で若しくはその他の塩
との混合物として含ませれば、透析液調製の際、蒸留水
に塩基性の重炭酸塩含有層、中間層、有機酸含有層が順
次溶解して中性〜微アルカリ性に調整されるため、炭酸
ガスの発生を防ぐことができ、好都合である。
As a dosage form of the dialysis agent of the present invention, a laminated type spherical granule comprising a core substance (core), an inner layer, an intermediate layer and an outer layer is preferable. The preferred compound groups for forming each of these layers are as follows. Core substance (core) Sodium chloride inner layer Solid organic acid (citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid, malic acid),
Acid salt (calcium chloride, magnesium chloride) Sodium chloride, potassium chloride, glucose intermediate layer Sodium chloride, potassium chloride, sodium acetate, potassium acetate, calcium gluconate, glucose outer layer bicarbonate (sodium hydrogen carbonate, potassium carbonate), sodium chloride , Potassium chloride, sodium acetate, potassium acetate, calcium gluconate, glucose In the above, the compound contained in the outer layer is particularly important.
That is, if the outer layer contains bicarbonate alone or as a mixture with other salts, the basic bicarbonate-containing layer, the intermediate layer, and the organic acid-containing layer are sequentially dissolved in distilled water during the preparation of dialysate. Since it is adjusted to be neutral to slightly alkaline, the generation of carbon dioxide gas can be prevented, which is convenient.

【0012】本発明の積層型製剤は、公知の方法に基づ
いて製造できる。例えば、使用する化合物を固体の有機
酸、カルシウム及びマグネシウムを含む群、酢酸ナトリ
ウム及びブドウ糖を含む群、重炭酸塩を含む群の3群に
分け、各群の混合物をサンプルミル(不二パウダル社
製)等の粉砕機で微粉化する。次に粒径355〜500
μmの塩化ナトリウムを遠心流動型コーティング造粒装
置に入れ、ブドウ糖溶液を噴霧しながら前記微粉末を順
次粉末添加することによって球状の積層顆粒剤が得られ
る。
The layered preparation of the present invention can be produced by a known method. For example, the compounds to be used are divided into three groups, a group containing solid organic acids, calcium and magnesium, a group containing sodium acetate and glucose, and a group containing bicarbonate, and the mixture of each group is mixed with a sample mill (Fuji Paudal Company). Pulverized by a crusher such as Then the particle size is 355-500
Spherical laminated granules are obtained by putting sodium chloride (μm) into a centrifugal fluidized coating granulator and sequentially adding the fine powder while spraying a glucose solution.

【0013】本発明の透析用剤は、実質的に酸素ガスが
存在しない状態で保存すれば、より安定である。その包
装に当たっては、例えば窒素気流中あるいは炭酸ガス中
で酸素ガスバリヤー性の高い容器に充填し、密封すれば
よい。
The dialysis agent of the present invention is more stable if it is stored in the substantially absence of oxygen gas. For packaging, a container having a high oxygen gas barrier property may be filled in a nitrogen stream or carbon dioxide gas and sealed.

【0014】[0014]

【作用】従来pH調整剤として使用されていた液体の酢
酸若しくは乳酸に代えて固体の有機酸を用い、pH調整
剤と重炭酸塩が接触しないように多層型製剤にすること
により、重曹透析液調製に必要な全ての成分を含む安定
な製剤が得られる。また、顆粒剤としたことから、取り
扱い易く然も水に速やかに溶解する。
A solid organic acid is used in place of the liquid acetic acid or lactic acid conventionally used as a pH adjusting agent, and a sodium bicarbonate dialysate is prepared by forming a multi-layered preparation so that the pH adjusting agent and bicarbonate do not come into contact with each other. A stable formulation is obtained that contains all the ingredients necessary for its preparation. Moreover, since it is a granule, it is easy to handle and quickly dissolves in water.

【0015】[0015]

【実施例】以下の実施例に記載する「%」は重量によ
る。 実施例1 クエン酸80g、塩化カルシウム・2水和物88.4g
及び塩化マグネシウム・6水和物40.8gを万能撹拌
機(品川工業所製、SD−02型)で撹拌し、サンプル
ミル(不二パウダル製、粉砕機KIIW−1型)で粉砕し
て第1微粉末を得た。塩化カリウム59.6g、酢酸ナ
トリウム196.4g及びブドウ糖200gを前記と同
様にして混合、粉砕して第2微粉末を得た。さらに炭酸
水素ナトリウム1008gをサンプルミルで粉砕し第3
微粉末を得た。次に、粒子径355〜500μmの塩化
ナトリウム2430.8gを遠心流動型コーティング造
粒装置(フロイント産業社製、CF−360S型)に入
れ、回転させ(回転数500rpm)且つ50%ブドウ
糖溶液(溶媒は、エタノールと水が1:1の混合液)を
噴霧しながら先の第1微粉末、第2微粉末、第3微粉末
の順に添加し、球形の顆粒剤を得た。なお、前記噴霧の
液量は全量400mlとした。得られた顆粒剤を減圧下
40℃で5時間乾燥した後、分級して12〜24メッシ
ュの顆粒剤を得、目的の透析用剤とした。 粒度分布 12〜18メッシュ 82.3% 18〜24メッシュ 17.7% 比容積 0.828g/ml
EXAMPLES "%" in the following examples is by weight. Example 1 Citric acid 80 g, calcium chloride dihydrate 88.4 g
And 40.8 g of magnesium chloride hexahydrate were stirred with a universal stirrer (SD-02 type, manufactured by Shinagawa Kogyo Co., Ltd.) and crushed with a sample mill (Fuji Paudal, crusher KIIW-1 type). One fine powder was obtained. 59.6 g of potassium chloride, 196.4 g of sodium acetate and 200 g of glucose were mixed and pulverized in the same manner as above to obtain a second fine powder. Furthermore, 1008 g of sodium hydrogen carbonate was crushed with a sample mill and the third
A fine powder was obtained. Next, 2430.8 g of sodium chloride having a particle diameter of 355 to 500 μm was placed in a centrifugal fluidized coating granulation apparatus (CF-360S type manufactured by Freund Sangyo Co., Ltd.), rotated (rotation speed 500 rpm) and a 50% glucose solution (solvent). Was sprayed with a 1: 1 mixture of ethanol and water), and the first fine powder, the second fine powder and the third fine powder were added in this order to obtain spherical granules. The liquid volume of the spray was 400 ml in total. The obtained granules were dried under reduced pressure at 40 ° C. for 5 hours and then classified to obtain granules of 12 to 24 mesh, which was used as a target dialysis agent. Particle size distribution 12-18 mesh 82.3% 18-24 mesh 17.7% Specific volume 0.828 g / ml

【0016】実施例2 実施例1と同様にして、クエン酸80g、塩化カルシウ
ム・2水和物88.4g及び塩化マグネシウム・6水和
物40.8gから第1微粉末を、塩化ナトリウム63
0.8g、塩化カリウム59.6g、酢酸ナトリウム1
96.4g及びブドウ糖200gから第2微粉末を、さ
らに炭酸水素ナトリウム1008gから第3微粉末をそ
れぞれ得、粒子径355〜500μmの塩化ナトリウム
1800gに順次積層した(造粒装置による回転数:2
50rpm)。なお50%ブドウ糖溶液の噴霧液量は全
量400mlとした。以下の操作も実施例1と同様にし
て12〜24メッシュの顆粒剤を得、目的の透析用剤と
した。 粒度分布 12〜18メッシュ 99.6% 18〜24メッシュ 0.4% 比容積 0.802g/ml
Example 2 In the same manner as in Example 1, the first fine powder was prepared from 80 g of citric acid, 88.4 g of calcium chloride dihydrate and 40.8 g of magnesium chloride hexahydrate, and 63 g of sodium chloride.
0.8 g, potassium chloride 59.6 g, sodium acetate 1
A second fine powder was obtained from 96.4 g and 200 g of glucose, and a third fine powder was obtained from 1008 g of sodium hydrogencarbonate, which were sequentially laminated on 1800 g of sodium chloride having a particle diameter of 355 to 500 μm (rotation speed by a granulating device: 2
50 rpm). The amount of the 50% glucose solution sprayed was 400 ml in total. The following operations were carried out in the same manner as in Example 1 to obtain granules of 12 to 24 mesh, which was used as the target dialysis agent. Particle size distribution 12-18 mesh 99.6% 18-24 mesh 0.4% Specific volume 0.802 g / ml

【0017】実施例3 実施例1と同様にして、クエン酸80g、塩化カルシウ
ム・2水和物88.4g、塩化マグネシウム・6水和物
40.8g及び塩化カリウム59.6gから第1微粉末
を、塩化ナトリウム630.8g、酢酸ナトリウム19
6.4g及びブドウ糖200gから第2微粉末を、さら
に炭酸水素ナトリウム1008gから第3微粉末をそれ
ぞれ得、粒子径355〜500μmの塩化ナトリウム1
800gに順次積層した(造粒装置による回転数:40
0rpm)。なお50%ブドウ糖溶液の噴霧液量は全量
400mlとした。以下の操作も実施例1と同様にして
12〜24メッシュの顆粒剤を得、窒素気流中でポリエ
チレン−アルミ箔−ポリエチレンの三層ラミネートシー
ト製容器に充填し、密封した。 粒度分布 12〜18メッシュ 92.2% 18〜24メッシュ 7.8% 比容積 0.817g/ml
Example 3 In the same manner as in Example 1, 80 g of citric acid, 88.4 g of calcium chloride dihydrate, 40.8 g of magnesium chloride hexahydrate and 59.6 g of potassium chloride were used to produce a first fine powder. 630.8 g of sodium chloride and 19% of sodium acetate
A second fine powder was obtained from 6.4 g and glucose 200 g, and a third fine powder was obtained from sodium hydrogencarbonate 1008 g, and sodium chloride 1 having a particle diameter of 355 to 500 μm was obtained.
Sequentially stacked on 800 g (rotation speed by granulator: 40
0 rpm). The amount of the 50% glucose solution sprayed was 400 ml in total. The following operations were performed in the same manner as in Example 1 to obtain granules of 12 to 24 mesh, which were filled in a polyethylene-aluminum foil-polyethylene three-layer laminated sheet container in a nitrogen stream and sealed. Particle size distribution 12-18 mesh 92.2% 18-24 mesh 7.8% Specific volume 0.817 g / ml

【0018】〔試験例1〕実施例1、2及び3の透析用
剤をそれぞれガラス瓶に入れ、密栓して40℃にて3か
月間保存し(実施例3で製造した透析用剤のみ、ガラス
瓶内の空間部を窒素ガスで置換)、1か月経過毎に対照
との色差(ΔE)、凝集の有無、水に溶解後の炭酸水素
イオン濃度及びpHを測定した。前記溶解に際し、何れ
の試料も数分以内に溶解した。なお、色差は、対応する
実施例の透析用剤を5℃にて同様に保存して対照とし、
色差計(日本電色工業株式会社製、Σ80型)を用いて
測定した。炭酸水素イオン濃度及びpHは、試料10.
76gを蒸留水に溶かして1000mlとし、それぞれイ
オンクロマトグラフィー(横河電機株式会社製、IC−
500S型)及びpHメータ(堀場製作所製、F−16
型)を用いて測定した。それらの結果を表1に示した。
[Test Example 1] The dialysis agents of Examples 1, 2 and 3 were placed in glass bottles, respectively, and the bottles were tightly sealed and stored at 40 ° C. for 3 months (only the dialysis agents produced in Example 3 were glass bottles). The interior space was replaced with nitrogen gas), and the color difference (ΔE) from the control, the presence or absence of aggregation, the hydrogen carbonate ion concentration after dissolution in water, and the pH were measured every one month. At the time of the dissolution, all the samples were dissolved within a few minutes. The color difference was determined by storing the dialysis agent of the corresponding Example at 5 ° C. as a control,
It was measured using a color difference meter (Nippon Denshoku Industries Co., Ltd., Σ80 type). The hydrogen carbonate ion concentration and the pH were measured according to Sample 10.
Dissolve 76 g in distilled water to make 1000 ml, and perform ion chromatography (Yokogawa Electric Co., IC-
500S type and pH meter (H-16, F-16)
Type). The results are shown in Table 1.

【0019】[0019]

【表1】 [Table 1]

【0020】表1より、本発明透析用剤は、長期保存後
も外観(色)と炭酸水素ナトリウム含量が殆ど変化せ
ず、水に速やかに溶け、凝集物は生じないことが分か
る。
From Table 1, it can be seen that the dialysis agent of the present invention hardly changes in appearance (color) and sodium hydrogen carbonate content even after long-term storage, dissolves rapidly in water, and does not generate aggregates.

【0021】〔試験例2〕実施例1の透析用剤を100
0mlのポリエチレン容器に800g入れ、、容器内の上
部、中部、下部の3か所より試料を採取し、それぞれ1
0.76gを蒸留水に溶かして1000mlとし、ナトリ
ウムイオン濃度、カルシウムイオン濃度及び炭酸水素イ
オン濃度を測定した。それらの結果を表2に示した。
Test Example 2 100 parts of the dialysis agent of Example 1 was tested.
Put 800g in a 0ml polyethylene container and collect samples from the upper, middle and lower parts of the container.
0.76 g was dissolved in distilled water to 1000 ml, and sodium ion concentration, calcium ion concentration and hydrogen carbonate ion concentration were measured. The results are shown in Table 2.

【0022】[0022]

【表2】 [Table 2]

【0023】表2より、本発明透析用剤は、含量偏析が
ないことが分かる。
From Table 2, it can be seen that the dialysis agent of the present invention has no content segregation.

【0024】[0024]

【発明の効果】本発明の透析用剤は、長期保存が可能な
顆粒剤であり、取り扱い易く、その所定量又は計算量を
水に溶かすだけで重曹透析液が速やかに調製できる。
The dialysis agent of the present invention is a granule that can be stored for a long period of time, is easy to handle, and a sodium bicarbonate dialysate can be rapidly prepared by dissolving a predetermined amount or calculated amount thereof in water.

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 平6−237991(JP,A) 特開 平4−257522(JP,A) 特公 昭63−52009(JP,B1) (58)調査した分野(Int.Cl.7,DB名) A61M 1/14 - 1/28 A61K 9/08 ─────────────────────────────────────────────────── --Continued from the front page (56) References JP-A-6-237991 (JP, A) JP-A-4-257522 (JP, A) JP-B-63-52009 (JP, B1) (58) Field (Int.Cl. 7 , DB name) A61M 1/14-1/28 A61K 9/08

Claims (4)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】少なくともNa+ 、Ca++、Cl- 及びH
CO3 - を含有する透析液の調製に必要な電解質と薬理
学的に許容される固体の有機酸とを含有する積層型製剤
であって、前記有機酸を含み重炭酸塩を含まない層と重
炭酸塩を含み前記有機酸を含まない層が中間層を挟んで
積層されてなる透析用剤。
1. At least Na + , Ca ++ , Cl and H.
CO 3 - A multilayer preparation containing the electrolyte and pharmacologically organic acids acceptable solid necessary for the preparation of a dialysis solution containing a layer without bicarbonate containing the organic acid A dialysis agent comprising a layer containing a bicarbonate and not containing the organic acid, with an intermediate layer interposed therebetween.
【請求項2】固体の有機酸がクエン酸、酒石酸、マレイ
ン酸、オキサロ酢酸、イソクエン酸及びリンゴ酸からな
る群から選ばれた1種又は2種以上である請求項1に記
載の透析用剤。
2. The dialysis agent according to claim 1, wherein the solid organic acid is one or more selected from the group consisting of citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid and malic acid. .
【請求項3】積層型製剤が、芯物質(核)、内層、中間
層及び外層の多層構造を有し、芯物質が塩化ナトリウム
であり、内層に固体の有機酸が含まれ、外層に重炭酸塩
が含まれた球形顆粒剤である請求項1又は2に記載の透
析用剤。
3. A laminated preparation having a multilayer structure of a core substance (core), an inner layer, an intermediate layer and an outer layer, wherein the core substance is sodium chloride, the inner layer contains a solid organic acid, and the outer layer contains The dialysis agent according to claim 1 or 2, which is a spherical granule containing a carbonate.
【請求項4】実質的に酸素ガスが存在しない状態で保存
された請求項1に記載の透析用剤。
4. The dialysis agent according to claim 1, which is stored in a state in which oxygen gas is substantially absent.
JP17977293A 1993-04-02 1993-06-25 Baking soda dialysis agent Expired - Fee Related JP3384841B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP17977293A JP3384841B2 (en) 1993-04-02 1993-06-25 Baking soda dialysis agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10045293 1993-04-02
JP5-100452 1993-04-02
JP17977293A JP3384841B2 (en) 1993-04-02 1993-06-25 Baking soda dialysis agent

Publications (2)

Publication Number Publication Date
JPH06335527A JPH06335527A (en) 1994-12-06
JP3384841B2 true JP3384841B2 (en) 2003-03-10

Family

ID=26441476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP17977293A Expired - Fee Related JP3384841B2 (en) 1993-04-02 1993-06-25 Baking soda dialysis agent

Country Status (1)

Country Link
JP (1) JP3384841B2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7670491B2 (en) 1998-10-20 2010-03-02 Advanced Renal Technologies Buffered compositions for dialysis
US7186420B2 (en) 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
US8105258B2 (en) 1999-04-26 2012-01-31 Baxter International Inc. Citrate anticoagulation system for extracorporeal blood treatments
US6489301B1 (en) 1999-06-07 2002-12-03 Nipro Corporation Solid pharmaceutical preparation for dialysis and a process for producing the same
JP3714050B2 (en) * 1999-09-07 2005-11-09 ニプロ株式会社 Solid baking soda dialysis agent and method for producing the same
WO2001021233A1 (en) 1999-09-22 2001-03-29 Advanced Renal Technologies High citrate dialysate and uses thereof
WO2004067014A1 (en) * 2003-01-31 2004-08-12 Manac Inc. Solid preparation for dialysis and process for producing the same
WO2004066977A1 (en) * 2003-01-31 2004-08-12 Manac Inc. Solid agent for dialysis and process for producing the same
CN101933939A (en) * 2010-09-01 2011-01-05 刘思波 Malic acid bicarbonate external hemodialysis agent

Also Published As

Publication number Publication date
JPH06335527A (en) 1994-12-06

Similar Documents

Publication Publication Date Title
US6489301B1 (en) Solid pharmaceutical preparation for dialysis and a process for producing the same
JP3619921B2 (en) Bicarbonate solid dialysis agent
US20070190161A1 (en) Solid formulation for dialysis and process for producing the same
EP0177614B1 (en) Process for producing mixed electrolyte powder for use in bicarbonate dialysis
EP1192961B1 (en) Solid preparation for dialysis and process for producing the same
JP2015221815A (en) Solid preparation for dialysis
JP3384841B2 (en) Baking soda dialysis agent
JP3530235B2 (en) Hemodialysis agent
JP3398184B2 (en) Dialysis agent
JP3647898B2 (en) Sodium bicarbonate dialysis agent and method for producing the same
WO2018079022A1 (en) Hemodialysis agent a
JPH02311418A (en) Pharmaceutical for hemodialysis and its production
JP3415291B2 (en) Bicarbonate dialysis agent
EP1192960B1 (en) Solid preparation for dialysis and process for producing the same
EP3053597B1 (en) Solid dialysis a agent containing alkali metal diacetate, and two-part type low-acetate dialysis agent using same
JP2809971B2 (en) Hemodialysis preparation
JP4395995B2 (en) Preparation for dialysis and method for producing the same
JPH10259133A (en) Particulate agent for dialysis and its production
JP3947995B2 (en) Bicarbonate solid dialysis agent
JPH0338527A (en) Preparation for blood dialysis and its production
JPH11114054A (en) Solid dialysis agent
EP1086700B1 (en) A solid pharmaceutical composition for dialysate containing sodium bicarbonate and a process for producing the same
JP4328851B2 (en) Bicarbonate solid dialysate
JP2001327597A (en) Pharmaceutical preparation for solid sodium carbonate dialysis and method for preparing the same
JP3951284B2 (en) Solid preparation for dialysis and method for producing the same

Legal Events

Date Code Title Description
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081227

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091227

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091227

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091227

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101227

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101227

Year of fee payment: 8

LAPS Cancellation because of no payment of annual fees